Your browser doesn't support javascript.
loading
Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss.
Oza, Andrea M; DiStefano, Marina T; Hemphill, Sarah E; Cushman, Brandon J; Grant, Andrew R; Siegert, Rebecca K; Shen, Jun; Chapin, Alex; Boczek, Nicole J; Schimmenti, Lisa A; Murry, Jaclyn B; Hasadsri, Linda; Nara, Kiyomitsu; Kenna, Margaret; Booth, Kevin T; Azaiez, Hela; Griffith, Andrew; Avraham, Karen B; Kremer, Hannie; Rehm, Heidi L; Amr, Sami S; Abou Tayoun, Ahmad N.
Afiliação
  • Oza AM; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • DiStefano MT; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, Massachusetts.
  • Hemphill SE; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • Cushman BJ; Harvard Medical School, Boston, Massachusetts.
  • Grant AR; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • Siegert RK; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • Shen J; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • Chapin A; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • Boczek NJ; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • Schimmenti LA; Harvard Medical School, Boston, Massachusetts.
  • Murry JB; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts.
  • Hasadsri L; ARUP Laboratories, Salt Lake City, Utah.
  • Nara K; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Kenna M; Department of Otorhinolaryngology, Clinical Genomics and Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota.
  • Booth KT; Laboratory for Molecular Medicine, Partners Healthcare Personalized Medicine, Cambridge, Massachusetts.
  • Azaiez H; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Griffith A; Division of Hearing and Balance Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Avraham KB; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, Massachusetts.
  • Kremer H; Harvard Medical School, Boston, Massachusetts.
  • Rehm HL; Molecular Otolaryngology and Renal Research Laboratories, Department of Otolaryngology, University of Iowa Hospital and Clinics, Iowa City, Iowa.
  • Amr SS; The Interdisciplinary Graduate Program in Molecular Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa.
  • Abou Tayoun AN; Molecular Otolaryngology and Renal Research Laboratories, Department of Otolaryngology, University of Iowa Hospital and Clinics, Iowa City, Iowa.
Hum Mutat ; 39(11): 1593-1613, 2018 11.
Article em En | MEDLINE | ID: mdl-30311386
ABSTRACT
Due to the high genetic heterogeneity of hearing loss (HL), current clinical testing includes sequencing large numbers of genes, which often yields a significant number of novel variants. Therefore, the standardization of variant interpretation is crucial to provide consistent and accurate diagnoses. The Hearing Loss Variant Curation Expert Panel was created within the Clinical Genome Resource to provide expert guidance for standardized genomic interpretation in the context of HL. As one of its major tasks, our Expert Panel has adapted the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines for the interpretation of sequence variants in HL genes. Here, we provide a comprehensive illustration of the newly specified ACMG/AMP HL rules. Three rules remained unchanged, four rules were removed, and the remaining 21 rules were specified. These rules were further validated and refined using a pilot set of 51 variants assessed by curators and disease experts. Of the 51 variants evaluated in the pilot, 37% (19/51) changed category based upon application of the expert panel specified rules and/or aggregation of evidence across laboratories. These HL-specific ACMG/AMP rules will help standardize variant interpretation, ultimately leading to better care for individuals with HL.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Genoma Humano / Testes Genéticos / Perda Auditiva Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Genoma Humano / Testes Genéticos / Perda Auditiva Idioma: En Ano de publicação: 2018 Tipo de documento: Article